Skip to search formSkip to main contentSkip to account menu

NSC 182986

Known as: NSC-182986 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

diaziquone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors
SummaryForty-one patients with recurrent primary malignant brain tumors were treated with 2,5-diaziridinyl 3,6-bis… 
2004
2004
Phase 11 study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation
Seventeen patients with malignant gliomas recurrent after chemotherapy and/ or radiation failure were treated with… 
1988
1988
A Phase II Clinical Trial of Diaziquone in the Treatment of Patients with Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study
Twenty-six patients with measurable endometrial cancer refractory to standard therapy received AZQ [1,4-cyclohex-adiene-l,4… 
1987
1987
Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Diaziquone (AZQ) (NSC 182986), a lipid-soluble benzoquinone derivative, is presently being tested in a Phase III clinical trial… 
1985
1985
Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986).
We investigated the in vitro interaction with and antitumor effect on several murine and human leukemic cell lines of diaziquone… 
1984
1984
In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma.
An in vitro clonogenic assay was used to test the chemosensitivity of the human medulloblastoma cell line TE-671. Dose-response… 
1982
1982
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
2,5-Diaziridinyl-3,6-(carboethoxyamino)-1,4-benzoquinone (AZQ) is a rationally designed antitumor agent which possesses… 
1982
1982
A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
Aziridinylbenzoquinone (AZQ: NSC-182986), is a quinone derivative which has been shown to have activity in implanted murine tumor… 
1981
1981
Phase I study of aziridinylbenzoquinone (NSC 182986).
A phase I clinical study of aziridinylbenzoquinone (AZQ) was conducted in 33 patients with various types of advanced solid tumors… 
1981
1981
Clinical pharmacology of 2,5-diaziridinyl-3,6-bis-carboethoxyamino-1,4-benzoquinone, (AZQ, NSC 182986)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)